指南与共识泌尿生殖腹部CTMRUS

ACR适宜性标准®膀胱癌治疗后监测:2021更新

ACR Appropriateness Criteria® Post-Treatment Surveillance of Bladder Cancer: 2021 Update.
指南 / 共识 · J Am Coll Radiol · 2021-01-01

该指南由美国放射学会多学科专家小组基于文献与RAND/UCLA及GRADE方法制定,将膀胱癌治疗后监测患者分为三组:无成本无附加风险的非肌层浸润性膀胱癌、有症状或附加风险的非肌层浸润性膀胱癌、肌层浸润性膀胱癌,并针对各组给出影像监测推荐。

要点

  • 监测影像目标:检出新的或既往未发现的尿路上皮肿瘤、识别转移性疾病、评估治疗并发症。
  • 患者分层:非肌层浸润性无成本无附加风险、非肌层浸润性有症状或附加风险、肌层浸润性三组。
  • 推荐基于证据分级,证据不足时可辅以专家意见。

核心结论

  • 膀胱尿路上皮癌治疗后监测影像应依据患者风险分层(非肌层浸润性无/有症状或附加风险、肌层浸润性)选择适宜检查。

研究设计与样本

  • 美国放射学会适宜性标准指南,由多学科专家小组每年审查,基于同行评议文献广泛分析,采用RAND/UCLA适宜性方法和GRADE对影像及治疗操作适宜性进行评级。

诊断标准与关键数值

  • 证据不足或模棱两可时,专家意见可补充现有证据以推荐影像或治疗。
  • 患者分为三组:非肌层浸润性膀胱癌无成本无附加风险、非肌层浸润性膀胱癌有症状或附加风险、肌层浸润性膀胱癌。

临床应用与阅片要点

  • 日常阅片和报告时应首先确认患者所属风险分层,以选择对应的监测影像策略。
  • 报告需关注新发或未检出的尿路上皮肿瘤、转移性疾病及治疗并发症。

局限性

  • 原文未明确报告样本量、中心数及具体影像检查的敏感度、特异度等数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Urothelial cancer is the second most common cancer, and cause of cancer death, related to the genitourinary tract. The goals of surveillance imaging after the treatment of urothelial cancer of the urinary bladder are to detect new or previously undetected urothelial tumors, to identify metastatic disease, and to evaluate for complications of therapy. For surveillance, patients can be stratified into one of three groups: 1) nonmuscle invasive bladder cancer with no symptoms or additional risk factors; 2) nonmuscle invasive bladder cancer with symptoms or additional risk factors; and 3) muscle invasive bladder cancer. This document is a review of the current literature for urothelial cancer and resulting recommendations for surveillance imaging. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.

来源:J Am Coll Radiol,查看原文。版权归原作者所有。

引用

  1. Allen BC, Oto A, Akin O, et al. ACR Appropriateness Criteria® Post-Treatment Surveillance of Bladder Cancer: 2021 Update. J Am Coll Radiol. 2021. PMID: 33958107. doi:10.1016/j.jacr.2021.02.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。